INVESTABOT
Equity Research
XNAS · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-08-12. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-08-03. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Incyte Genomics (INCY) had 2 Form 144 pre-sale notices filed on 2026-08-05. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fi…
Incyte Genomics (INCY) had 2 Form 144 pre-sale notices filed on 2026-07-31. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fi…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-07-16. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-07-16. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-07-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-06-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-05-26. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Incyte Genomics (INCY) had 1 Form 144 pre-sale notice filed on 2026-05-19. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/12/2026 | CAGNONI PABLO J | President, Global Head of R&D | SELL | -10,803 | $120 | $1,296,792 |
| 8/5/2026 | CAGNONI PABLO J | President, Global Head of R&D | SELL | -10,640 | $123 | $1,305,422 |
| 8/5/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 2,207 | $106 | $234,979 |
| 8/5/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | SELL | -2,207 | $124 | $273,646 |
| 8/5/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | -2,207 | — | — |
| 8/3/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 6,055 | $105 | $638,379 |
| 8/3/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | SELL | -6,055 | $120 | $729,204 |
| 8/3/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | -6,055 | — | — |
| 7/31/2026 | CAGNONI PABLO J | President, Global Head of R&D | SELL | -15,888 | $120 | $1,901,794 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 2,918 | $61 | $178,523 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 2,284 | $64 | $146,747 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 2,709 | $62 | $167,308 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 3,148 | $69 | $216,016 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 2,072 | $72 | $149,039 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 9,459 | $72 | $683,602 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 2,623 | $75 | $196,148 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 2,864 | $78 | $222,447 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 1,643 | $81 | $132,262 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 3,023 | $83 | $251,514 |
| 7/31/2026 | Mayes Patrick A | EVP & Chief Scientific Officer | OPTION_EXERCISE | 1,642 | $85 | $139,586 |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| 8/12/2026 | PABLO CAGNONI | — | 10,803 | SEC |
| 8/5/2026 | PATRICK A MAYES | — | 2,207 | SEC |
| 8/5/2026 | PABLO CAGNONI | — | 10,640 | SEC |
| 8/3/2026 | PATRICK A MAYES | — | 6,055 | SEC |
| 7/31/2026 | PATRICK A MAYES | — | 41,899 | SEC |
| 7/31/2026 | PABLO CAGNONI | — | 15,888 | SEC |
| 7/16/2026 | MOHAMED ISSA | — | 1,093 | SEC |
| 7/16/2026 | STEVEN STEIN | — | 1,877 | SEC |
| 7/15/2026 | STEVEN STEIN | — | 28,237 | SEC |
| 6/4/2026 | THOMAS R TRAY | — | 2,639 | SEC |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| 5/6/2026 | — | — | — | — | SEC |